Importance of systolic blood pressure in older Americans

Hypertension

Volumn 35, Issue 5, 2000, Pages 1021-1024

  Izzo Jr , Joseph L ^a,b   Levy, Daniel ^a   Black, Henry R ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Blood pressure; Clinical advisory; Elderly; Hypertension, detection and control

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

AGED; AGING; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIAGNOSTIC VALUE; HEALTH CARE COST; HUMAN; HYPERTENSION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; UNITED STATES; BLOOD PRESSURE; PATHOPHYSIOLOGY; REVIEW; SYSTOLE;

AGED; BLOOD PRESSURE; HUMANS; HYPERTENSION; SYSTOLE; UNITED STATES;

EID: 0034181905     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.5.1021     Document Type: Article

References (25)

1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997;157:2413-2446.
2. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Laborthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
3. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella E. J. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26:60-69.
4. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Arch Intern Med. 1992;152:56-64.
5. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
6. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure: insights into the time course of and risk factors for hypertensive left ventricular dysfunction. JAMA. 1996;275:1557-1562.
7. Kostis JB, Davis BR, Cutler J, Grimm RH, Jr, Berge KG, Cohen JD, Lacy CR, Perry HM, Blaufox MD, Wasertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group. Lancet. 1997;351:1755-1762.
8. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease: Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877-884.
9. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br Med J. 1998;317:713-720.
11. Sowers JR, Reed J. Clinical advisory statement: treatment of hypertension and diabetes. J Clin Hypertens. 2000;2:132-133.
12. Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med. 1993;329:1912-1917.
13. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure more important than systolic blood pressure in predicting coronary heart disease events? Circulation. 1999;100:354-360.
14. O'Rourke M. Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. Hypertension. 1990;15:339-347.
15. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
16. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension. 1993;23:275-285.
17. Lloyd-Jones DM. Impact of systolic versus diastolic blood pressure level of JNC-VI blood pressure stage classification. Hypertension. 1999;34: 381-385.
18. Madhaven S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23:395-401.
19. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. Am J Cardiology. 1971;27:335-345.
20. Dustan HP. 50th anniversary historical article: hypertension. J Am Coll Cardiol. 1999;33:595-597.
21. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18.
22. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older patients with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
23. Staessen JA, Thijs L, Fagard R, O'Brien EG, Clement D, de Leeuw PW, Mancia G, Nachev C, Palantini P, Prati G, Tuomilehto J, Webster J. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension: Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539-546.
24. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Webster P-O, Hedner T, deFaire U, for the STOP-Hypertension-2 Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
25. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:14-153.